375 related articles for article (PubMed ID: 25893495)
1. [Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard].
Bonnet U; Mahler H
Fortschr Neurol Psychiatr; 2015 Apr; 83(4):221-31. PubMed ID: 25893495
[TBL] [Abstract][Full Text] [Related]
2. Baths salts, spice, and related designer drugs: the science behind the headlines.
Baumann MH; Solis E; Watterson LR; Marusich JA; Fantegrossi WE; Wiley JL
J Neurosci; 2014 Nov; 34(46):15150-8. PubMed ID: 25392483
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Cannabinoids.
Mills B; Yepes A; Nugent K
Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
[TBL] [Abstract][Full Text] [Related]
4. The Synthetic Cannabinoids Phenomenon.
Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
[TBL] [Abstract][Full Text] [Related]
5. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part 1--cannabinoids and cathinones.
Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A
Ann Agric Environ Med; 2012; 19(4):857-70. PubMed ID: 23311820
[TBL] [Abstract][Full Text] [Related]
6. Designer Drugs 2.0.
Huestis MA; Tyndale RF
Clin Pharmacol Ther; 2017 Feb; 101(2):152-157. PubMed ID: 28084644
[TBL] [Abstract][Full Text] [Related]
7. Spice/K2 drugs--more than innocent substitutes for marijuana.
Zawilska JB; Wojcieszak J
Int J Neuropsychopharmacol; 2014 Mar; 17(3):509-25. PubMed ID: 24169044
[TBL] [Abstract][Full Text] [Related]
8. [Synthetic drugs: the new low-cost landscape of drugs].
Karila L; Petit A; Cottencin O; Coscas S; Reynaud M
Rev Prat; 2012 May; 62(5):664-6. PubMed ID: 22730798
[TBL] [Abstract][Full Text] [Related]
9. [Effect and occurrence of synthetic cannabinoids].
Tuv SS; Strand MC; Karinen R; Øiestad EL; Christophersen AS; Vindenes V
Tidsskr Nor Laegeforen; 2012 Oct; 132(20):2285-8. PubMed ID: 23736196
[TBL] [Abstract][Full Text] [Related]
10. New and Emerging Illicit Psychoactive Substances.
Graddy R; Buresh ME; Rastegar DA
Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
[TBL] [Abstract][Full Text] [Related]
11. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
Liechti M
Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
[TBL] [Abstract][Full Text] [Related]
12. [Cathinones use in Paris].
Batisse A; Grégoire M; Marillier M; Fortias M; Djezzar S
Encephale; 2016 Aug; 42(4):354-60. PubMed ID: 26847479
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.
Spiller HA; Ryan ML; Weston RG; Jansen J
Clin Toxicol (Phila); 2011 Jul; 49(6):499-505. PubMed ID: 21824061
[TBL] [Abstract][Full Text] [Related]
14. Neurochemical basis of cannabis addiction.
Maldonado R; Berrendero F; Ozaita A; Robledo P
Neuroscience; 2011 May; 181():1-17. PubMed ID: 21334423
[TBL] [Abstract][Full Text] [Related]
15. [Cannabinoid and cathinone designer drugs - the workings and selected methods of analysis].
Nędza J; Polaniak R; Bułdak RJ; Majchrzak M; Margasiń-Ska J; Rojkiewicz M; Celiński R; Grochowska-Niedworok E
Pol Merkur Lekarski; 2016 Jul; 41(241):56-59. PubMed ID: 27734824
[TBL] [Abstract][Full Text] [Related]
16. Neurobiology of cannabis addiction.
Jain R; Balhara YP
Indian J Physiol Pharmacol; 2008; 52(3):217-32. PubMed ID: 19552052
[TBL] [Abstract][Full Text] [Related]
17. Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces.
Loeffler G; Hurst D; Penn A; Yung K
Mil Med; 2012 Sep; 177(9):1041-8. PubMed ID: 23025133
[TBL] [Abstract][Full Text] [Related]
18. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature.
Cottencin O; Rolland B; Karila L
Curr Pharm Des; 2014; 20(25):4106-11. PubMed ID: 24001292
[TBL] [Abstract][Full Text] [Related]
19. A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure.
Gudsoorkar VS; Perez JA
Methodist Debakey Cardiovasc J; 2015; 11(3):189-91. PubMed ID: 26634029
[TBL] [Abstract][Full Text] [Related]
20. Stimulant and Designer Drug Use: Primary Care Management.
Klega AE; Keehbauch JT
Am Fam Physician; 2018 Jul; 98(2):85-92. PubMed ID: 30215997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
